Hypothesis

Senescent astrocytes in the aging brain do not merely drive complement‑mediated synapse loss; they simultaneously secrete complement inhibitors (e.g., CD55, factor H) that restrain microglial phagocytosis via CR3. This dual output creates a hostage‑negotiator SASP that limits runaway pruning while still signaling tissue damage. Removing these cells with senolytics eliminates both the pro‑pruning C3 and the anti‑pruning brakes, predicting a net increase in complement‑driven synapse elimination and accelerated cognitive decline.

Mechanistic Reasoning

1. SASP composition – Senescent astrocytes upregulate C3 as part of the inflammatory SASP ([1]) but also induce expression of complement regulatory proteins through a NF‑κB‑dependent feedback loop that aims to protect neighboring neurons from excessive complement activation (see neuroprotective roles of C1q and complement in BBB integrity) ([2], [3]).
2. Cell‑cell signaling – Secreted CD55 and factor H bind to C3b on synapses, preventing formation of the C5 convertase and thus limiting microglial CR3‑mediated engulfment. This creates a local "checkpoint" that depends on the continued presence of senescent astrocytes.
3. Senolytic intervention – Drugs such as dasatinib + quercetin selectively clear senescent cells ([4]). By ablating the astrocytic source, the inhibitory checkpoint is lost while residual microglial C1q/C3 (potentially from other sources or persisted opsonins) remains, tipping the balance toward unchecked pruning.

Testable Predictions

• Prediction 1: In aged mice, senolytic treatment will reduce astrocytic senescence markers (p16^INK4a^, SA‑β‑gal) but will increase synaptic C3b deposition and microglial phagocytic synapses compared with vehicle controls.
• Prediction 2: Cognitive performance (e.g., Morris water maze) will decline more sharply after senolysis despite lower overall SASP cytokine levels.
• Prediction 3: Co‑administration of a complement inhibitor (e.g., anti‑C5 antibody or factor H mimetic) will rescue synaptic density and cognitive function in senolytic‑treated mice.

Experimental Design

• Animals: 20‑month‑old C57BL/6J mice, n=10 per group.
• Groups: (1) Vehicle, (2) Senolytic (dasatinib + quercetin), (3) Senolytic + anti‑C5 antibody, (4) Isotype control.
• Readouts (2 weeks post‑treatment):
  • Immunofluorescence for astrocytic senescence (p16, SA‑β‑gal) and neuronal synapses (synaptophysin, PSD‑95).
  • Quantification of C3b/iC3b puncta colocalized with synapses.
  • Microglial phagocytic assay (Iba1^+^ synapses internalized).
  • Complement regulator levels (CD55, factor H) in cortical lysates via ELISA.
  • Behavioral assays: Morris water maze, novel object recognition.
• Expected Outcome: Senolytic alone shows ↓ senescence markers, ↑ C3b synapses, ↓ regulators, ↓ behavior; addition of complement inhibition normalizes synapse loss and cognition.

Falsifiability

If senolytic treatment does not increase synaptic C3b deposition or worsen cognition, or if complement inhibition fails to rescue the phenotype, the hypothesis that senescent astrocytes act as complement‑balancing hostage negotiators would be refuted. Conversely, confirmation would support a dual‑role model and advise combinatorial senolytic‑complement strategies for neurodegenerative disease.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC12821280/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC6538225/ [3] https://www.annualreviews.org/content/journals/10.1146/annurev-immunol-101921-035639 [4] https://onlinelibrary.wiley.com/doi/full/10.1111/jnc.14860